Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: Enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies

Journal of Medical Genetics

Volumn 43, Issue 11, 2006, Pages 856-862

  Karppinen, S M ^a   Barkardottir, R B ^b   Backenhorn, K ^c   Sydenham, T ^d   Syrjakoski K ^e   Schleutker, J ^e   Ikonen, T ^e   Pylkas K ^a   Rapakko, K ^a   Erkko, H ^a   Johannesdottir, G ^b   Gerdes, A M ^d   Thomassen, M ^d   Agnarsson, B A ^b   Grip, M ^a   Kallioniemi, A ^e   Kere, J ^f   Aaltonen, L A ^f   Arason, A ^b   Moller P ^g   Kruse, T A ^d   Borg, A ^c   Winqvist, R ^a   more..

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF TAMPERE   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CYSTEINE; SERINE;

ADOLESCENT; ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RISK; CARBOXY TERMINAL SEQUENCE; COLORECTAL CANCER; CONTROLLED STUDY; DNA SEQUENCE; FAMILIAL DISEASE; FEMALE; GEL ELECTROPHORESIS; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 33751242758     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2006.041731     Document Type: Article

References (32)

1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-24.
2. Miki Y, Swensen J, Shaffuck-Eidens P, Fufreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Narris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barret JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
3. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
4. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-02.
5. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, and the Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
6. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002;86:76-83.
7. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6.
8. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339-47.
9. Thai TH, Du F, Tsan JT, Jin Y, Phung A, Spillman MA, Massa HF, Muller CY, Ashfaq R, Mathis JM, Miller DS, Trask BJ, Baer R, Bowcock AM. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet 1998;7:195-202.
10. Ghimenti C, Sensi E, Presciuttini S, Brunetti IM, Conte P, Bevilacqua G, Caligo MA. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. Genes Chromosomes Cancer 2002;33:235-42.
11. Karppinen SM, Heikkinen K, Rapakko K, Winqvist R. Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer. J Med Genet 2004;41:e114.
12. Jin Y, Xu XL, Yang MC, Wei F, Ayi TC, Bowcock AM, Baer R. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. Proc Natl Acad Sci USA 1997;94:12075-80.
13. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997;90:425-35.
14. Westermark UK, Reyngold M, Olshen AB, Baer R, Jasin M, Moynahan ME. BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol Cell Biol 2003;23:7926-36.
15. Kleiman FE, Manley JL. Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50. Science 1999;285:1576-9.
16. Kleiman FE, Manley JL. The BARD1-CstF-50 interaction links mRNA 3′ end formation to DNA damage and tumor suppression. Cell 2001;104:743-53.
17. Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C, Leutz A. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 1999;18:3316-23.
18. Schuchner S, Tembe V, Rodriguez JA, Henderson BR. Nuclear targeting and cell cycle regulatory function of human BARD1. J Biol Chem 2005;280:8855-61.
19. Irminger-Finger I, Leung WC, Li J, Dubois-Dauphin M, Harb J, Feki A, Jefford CE, Soriano JV, Jaconi M, Montesano R, Krause KH. Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. Mol Cell 2001;8:1255-66.
20. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MCW, Hwang LY, Bowcock AM, Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 1996;14:430-40.
21. Brzovic PS, Meza JE, King MC, Klevit RE. BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions. J Biol Chem 2001;276:41399-406.
22. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 2001;276:14537-40.
23. Sauer MK, Andrulis IL. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer. J Med Genet 2005;42:633-8.
24. Jefford CE, Feki A, Harb J, Krause KH, Irminger-Finger I. Nuclear-cytoplasmic translocation of BARD1 is linked to its apoptotic activity. Oncogene 2004;23:3509-20.
25. Feki A, Jefford CE, Berardi P, Wu JY, Cartier L, Krause KH, Irminger-Finger I. BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase. Oncogene 2005;24:3726-36.
26. Spahn L, Petermann R, Siligan C, Schmid JA, Aryee DN, Kovar H. Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. Cancer Res 2002;62:4583-7.
27. Körkkö J, Annunen S, Pihlajamaa T, Prockop DJ, Ala-Kokko L. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci USA 1998;95:1681-5.
28. Syvänen AC. Solid-phase minisequencing as a tool to detect DNA polymorphism. Methods Mol Biol 1998;98:291-8.
29. Ishitobi M, Miyoshi Y, Hasegawa S, Egawa C, Tamaki Y, Monden M, Noguchi S. Mutational analysis of BARD1 in familial breast cancer patients in Japan. Cancer Lett 2003;200:1-7.
30. Vahteristo P, Syrjakoski K, Heikkinen T, Eerola H, Aittomaki K, von Smitten K, Holli K, Blomqvist C, Kallioniemi OP, Nevanlinna H. BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. Eur J Hum Genet 2006;14:167-72.
31. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR, CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
32. Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen Q, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003;63:8153-7.